Events

Pharmaceutical Life Cycle Management: Updates on Navigating the IP, FDA and Antitrust Terrain

Events / Wednesday, April 5, 2017

There’s been a sea change in the political climate. The regulatory forecast is still uncertain, and pharmaceutical evolution continues to develop.

Efforts to extend the life cycle of pharmaceutical products frequently involve innovations and improvements in product design, formulation, route of administration and treatment indications. In addition, negotiation of agreements with competitors, including generic and biosimilar manufacturers, is frequently employed as part of a life cycle management strategy. However, recent changes in patent, regulatory and antitrust laws have introduced considerable complexity and risk into these strategies.

Be prepared for what the next year may bring by attending this important webinar, which brings together our experienced professionals to talk about these issues and approaches for successful pharmaceutical life cycle management.

Presenters:
  • Carl W. Hittinger, Partner, Philadelphia
  • Lee H. Rosebush, Partner, Washington, D.C.
  • Lance L. Shea, Partner, Washington, D.C.
  • S. Maurice Valla, Partner, Philadelphia

Blog

In The Blogs

Previous Next
Antitrust Advocate
Carl Hittinger, Jeanne-Michele Mariani Examine Drug Price Spikes and Antitrust Laws
By Carl W. Hittinger, Jeanne-Michele Mariani
December 18, 2018
Partner Carl Hittinger and Associate Jeanne-Michele Mariani authored an article published by The Legal Intelligencer on Nov. 30, 2018. The article, “Price Hikes and Spikes and the Antitrust Laws,” uses the well-known example of “Pharma...
Read More ->
IP Intelligence: Insight on Intellectual Property
The Federal Circuit Weighs In on Evidentiary Considerations for Famous Marks and Analyzes Third-Party Usage
December 18, 2018
The Court of Appeals for the Federal Circuit recently held that the Trademark Trial and Appeal Board (TTAB) erred in concluding that there is no likelihood of confusion between Omaha Steaks International’s registered trademarks and Greater...
Read More ->
Health Law Update
Physician Hospitalist Group Settles with OCR and Enters Into a Resolution Agreement for Failure to Have HIPAA Policies and Business Associate Agreement in Place
December 18, 2018
On Dec. 5, 2018, the Office for Civil Rights (OCR) of the U. S. Department of Health and Human Services (HHS) announced that Advanced Care Hospitalists PL (ACH) had entered into a $500,000 settlement and resolution agreement (RA) resulting...
Read More ->
Antitrust Advocate
Carl Hittinger, Jeanne-Michele Mariani Assess Justice Kavanaugh's Testimony Regarding Antitrust Law
By Carl W. Hittinger, Jeanne-Michele Mariani
November 13, 2018
Partner Carl Hittinger and Associate Jeanne-Michele Mariani authored an article published Oct. 26, 2018, by The Legal Intelligencer. The article, “Justice Kavanaugh’s Antitrust Testimony Before the Senate Judiciary Committee,” examines the...
Read More ->
IP Intelligence: Insight on Intellectual Property
PTAB Denies Institution Despite Petitioner Demonstrating Reasonable Likelihood of Prevailing With Respect to at Least One Claim
By David N. Farsiou
November 12, 2018
In SAS Institute v. Iancu, 138 S. Ct. 1348, 1351 (2018), the Supreme Court held that when the Patent Trial and Appeal Board (the Board) institutes an inter partes review, it must decide the patentability of all the claims the petitioner...
Read More ->